Loading clinical trials...
Loading clinical trials...
The purposes of this study are to determine: * the largest dose of AQ4N that can be safely given once a week for three weeks out of a 4 week cycle * the side effects of AQ4N when given on the above s...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Novacea
NCT00131014 · Non-Hodgkin's Lymphoma, Hodgkin's Disease, and more
NCT06823167 · Solid Malignancies, Hematologic Malignancies
NCT05735717 · Hematologic Malignancy, Acute Leukemia, and more
NCT06927297 · Advanced Solid Tumor Malignancies, Advanced Solid Malignancies
NCT06667687 · Non-Hodgkin's Lymphoma
Weiler Hospital of Albert Einstein College of Medicine
The Bronx, New York
Cancer Therapy & Research Center / Institute for Drug Development
San Antonio, Texas
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions